Document is current

Article History

Accepted: 6 December 2024

First Online: 6 January 2025

Competing interests

: F.R.H. has acted as an adviser of Amgen, AstraZeneca, Bicara Therapeutics, BMS, Daiichi, G1 Therapeutics, Genentech/Roche, Genzyme/Sanofi, GSK, Merck, Merus Therapeutics, Nectin Therapeutics, NextCure, Novartis, OncoCyte, Oncohost and Regeneron. S.P. has acted as a consultant and/or adviser or speaker for AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Nuvation Bio, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda and Zymeworks. J.J.Z. has acted as a consultant and/or adviser or speaker or received research funding from AstraZeneca, Beigene, Bicara, Bristol Myers Squibb, Catalyst, GenePlus, Helius, Hengrui, Innovent Biologics, Johnson & Johnson, Merck, Novartis, OrigMed, Oncohost, Roche, Summit, Takeda and Varian. K.P. has acted as a consultant or adviser for Abion, BeiGene, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Merus and Zymeworks; data monitoring committee for BeiGene, Incyte, and Merck Sharp and Dohme. The other authors declare no competing interests.